Leap Therapeutics, Inc. (LPTX)

Leap Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	71.61	66.61	115.21	53.05	4.99
Cash & Cash Equivalents	71.61	66.61	115.21	53.05	4.99
Cash Growth	7.51%	-42.19%	117.17%	963.15%	-71.75%
Receivables	0.77	2.1	1.19	0.07	0.19
Other Current Assets	-0.78	-0.76	0.48	-0.85	-0.93
Total Current Assets	71.6	67.95	116.87	52.27	4.24
Property, Plant & Equipment	0.26	0.69	0.5	0.59	1.15
Other Long-Term Assets	0.97	1.71	0.54	1.5	2.06
Total Long-Term Assets	1.23	2.4	1.04	2.1	3.21
Total Assets	72.83	70.35	117.91	54.37	7.45
Accounts Payable	6.47	5.66	4.19	2.72	4.57
Deferred Revenue	0	0	0	1.5	0
Other Current Liabilities	6.22	5.57	5.8	3.16	3.92
Total Current Liabilities	12.68	11.23	9.99	7.37	8.49
Long-Term Debt	0	0.26	0.04	0.14	0.55
Other Long-Term Liabilities	0	0	0	0.2	0.16
Total Long-Term Liabilities	0	0.26	0.04	0.35	0.71
Total Liabilities	12.68	11.49	10.02	7.72	9.2
Total Debt	0	0.26	0.04	0.14	0.55
Debt Growth	-	608.11%	-74.31%	-73.91%	-
Retained Earnings	-399.58	-318.17	-263.57	-222.99	-195.17
Comprehensive Income	0.11	0.13	-0.27	-0.58	0.08
Shareholders' Equity	60.14	58.87	107.89	46.65	-1.75
Net Cash / Debt	71.61	66.35	115.17	52.91	4.44
Net Cash / Debt Growth	7.93%	-42.39%	117.69%	1092.14%	-74.88%
Net Cash Per Share	3.50	5.86	13.42	8.92	1.97
Working Capital	58.91	56.73	106.89	44.9	-4.25
Book Value Per Share	2.94	5.20	12.57	7.86	-0.77

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).